0H22 vs AMBEA: Side-by-Side Comparison
Compare Bioinvent International AB (0H22) and Ambea AB (AMBEA) side by side: valuation, financials, growth and model signals on Bullrun.
| Metric | 0H22 | AMBEA |
|---|---|---|
| Company | Bioinvent International AB | Ambea AB |
| Country / Exchange | Sweden · LSE | Sweden · ST |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Care Facilities |
| Market cap | — | SEK 12.54B |
| P/E ratio | — | 18.3 |
| Dividend yield | — | 1.67% |
| Valuation model | — | 5.8% undervalued |
| Revenue (latest FY) | — | — |
| Revenue growth YoY | — | — |
| Net income | — | SEK 620.00M |
| Gross margin | — | — |
| Diluted EPS | — | 7.20 |